Centre de Recherche du Centre Hospitalier de l’Universite de Montreal, Canada
Dr Meriem Messaoudene is specialized in human tumor immunology since her basic training at université Pierre et Marie Curie and Institut Pasteur (Paris, France). After a PhD training program at université Paris XI in NK cells and human metastatic melanoma, she undertook a post-doctoral study on the efficiency of the new class of T cell bispecific antibodies in breast cancer at Pr. Laurence Zitvogel’s lab (Institut Gustave Roussy, France) with a close collaboration to study the impact of the microbiota in the efficiency of the immune checkpoint blockades in NSCLC. Since 2018, she has started a post-doctoral at CRCHUM (Montreal, Canada) on microbiota and cancer in the lab of Dr Bertrand Routy with the challenge to develop new therapeutic strategies to safely increase ICB response through the manipulation of microbiota.